# Guardian Pharmacy Services, Inc.: overview

GRDN · NYSE · CIK 1802255 · [Consumer staples](/sectors/consumer-staples.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/grdn.md) · [Financials](/companies/grdn/financials.md) · [Filings](/companies/grdn/filings.md) · [Insiders](/companies/grdn/insiders.md)

Latest reported revenue: [$351.8m](/filings/0001193125-26-338074.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-338074).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [314](/filings/0001193125-25-274298.md) | [339 d](/filings/0001193125-26-102172.md) | [329](/filings/0001193125-26-209021.md) | [344](/filings/0001193125-26-338074.md) | [377](/filings/0001193125-25-274298.md) | [398 d](/filings/0001193125-26-102172.md) | [337](/filings/0001193125-26-209021.md) | [352](/filings/0001193125-26-338074.md) |
| Gross margin | % | [19.4%](/filings/0001193125-25-274298.md) | [19.8% d](/filings/0001193125-26-102172.md) | [19.5%](/filings/0001193125-26-209021.md) | [19.8%](/filings/0001193125-26-338074.md) | [19.8%](/filings/0001193125-25-274298.md) | [21.5% d](/filings/0001193125-26-102172.md) | [22.7%](/filings/0001193125-26-209021.md) | [22.8%](/filings/0001193125-26-338074.md) |
| Operating margin | % | [(33.3%)](/filings/0001193125-25-274298.md) | [4.9% d](/filings/0001193125-26-102172.md) | [3.9%](/filings/0001193125-26-209021.md) | [3.7%](/filings/0001193125-26-338074.md) | [4.3%](/filings/0001193125-25-274298.md) | [7.7% d](/filings/0001193125-26-102172.md) | [5.3%](/filings/0001193125-26-209021.md) | [5.9%](/filings/0001193125-26-338074.md) |
| Net margin | % | [(38.8%)](/filings/0001193125-25-274298.md) | [3.5% d](/filings/0001193125-26-102172.md) | [2.9%](/filings/0001193125-26-338074.md) | [2.6%](/filings/0001193125-26-338074.md) | [2.6%](/filings/0001193125-25-274298.md) | [5.3% d](/filings/0001193125-26-102172.md) | [3.9%](/filings/0001193125-26-338074.md) | [6.2%](/filings/0001193125-26-338074.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Free cash flow | $m | [(4.4) d](/filings/0001193125-25-274298.md) | [20.1 d](/filings/0001193125-26-102172.md) | not reported | not reported | [24.2 d](/filings/0001193125-25-274298.md) | [34.1 d](/filings/0001193125-26-102172.md) | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL not reported.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: |
| Revenue | $m | [1,228](/filings/0001193125-26-102172.md) | [1,449](/filings/0001193125-26-102172.md) |
| Gross margin | % | [19.9%](/filings/0001193125-26-102172.md) | [20.2%](/filings/0001193125-26-102172.md) |
| Operating margin | % | [(5.1%)](/filings/0001193125-26-102172.md) | [5.0%](/filings/0001193125-26-102172.md) |
| Net margin | % | [(9.0%)](/filings/0001193125-26-102172.md) | [3.4%](/filings/0001193125-26-102172.md) |
| Diluted EPS | $ per share | not reported | not reported |
| Free cash flow | $m | [43.3](/filings/0001193125-26-102172.md) | [86.8](/filings/0001193125-26-102172.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL not reported.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/grdn/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $135.7m | 3,241,612 |  | Added +882,255 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $72.4m | 1,729,032 |  | Reduced −36,087 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $66.0m | 1,575,989 |  | Reduced −180,385 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $57.8m | 1,379,750 |  | Added +154,207 |
| [Woodline Partners LP](/funds/1784547.md) | 2026-06-30 | $54.7m | 1,306,340 |  | Added +22 |
| [Valiant Capital Management, L.P.](/funds/1452689.md) | 2026-06-30 | $49.7m | 1,186,658 |  | Unchanged |
| [Boston Partners](/funds/1386060.md) | 2026-06-30 | $40.8m | 983,868 |  | Reduced −33,815 |
| [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $40.5m | 966,206 |  | Added +13,254 |
| [TimesSquare Capital Management, LLC](/funds/1313816.md) | 2026-06-30 | $39.8m | 951,637 |  | Reduced −125,837 |
| [LOOMIS SAYLES & CO L P](/funds/312348.md) | 2026-06-30 | $36.4m | 869,836 |  | Reduced −61,853 |

## Recent filings

[All 216 filings](/companies/grdn/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-28 | 17:02 ET | [SCHEDULE 13D/A](/filings/0001193125-26-405492.md) | Ownership report, active investor, amended | 0001193125-26-405492 |
| 2026-09-10 | 16:05 ET | [8-K](/filings/0001193125-26-387858.md) | 8.01 Other events | 0001193125-26-387858 |
| 2026-08-06 | 16:17 ET | [10-Q](/filings/0001193125-26-338074.md) | Quarterly report, period 2026-06-30 | 0001193125-26-338074 |
| 2026-08-06 | 16:12 ET | [8-K](/filings/0001193125-26-338032.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-338032 |
| 2026-06-22 | 16:35 ET | [8-K](/filings/0001193125-26-277596.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-277596 |
| 2026-05-28 | 16:11 ET | [8-K](/filings/0001193125-26-245235.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-245235 |
| 2026-05-07 | 16:12 ET | [8-K](/filings/0001193125-26-211924.md) | 5.07 Shareholder vote results | 0001193125-26-211924 |
| 2026-05-06 | 16:16 ET | [10-Q](/filings/0001193125-26-209021.md) | Quarterly report, period 2026-03-31 | 0001193125-26-209021 |
| 2026-05-06 | 16:13 ET | [8-K](/filings/0001193125-26-208989.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-208989 |
| 2026-03-26 | 07:18 ET | [DEF 14A](/filings/0001193125-26-125070.md) | Proxy statement, period 2026-05-05 | 0001193125-26-125070 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-102172.md), filed Mar 11, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/f8c5db25-96f1-4953-a423-2d96fec88199)

## About the filer

- CIK: 1802255
- Tickers: GRDN
- Exchange: NYSE
- SIC code: 5912 Retail-Drug Stores and Proprietary Stores
- State of incorporation: GA
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.